v3.25.4
Consolidated Statements of Operations - USD ($)
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Revenue:    
Total revenue $ 32,000
Costs and expenses:    
Cost of revenue 424,000
Sales, general and administrative compensation (inclusive of stock-based compensation) 873,000 718,000
Sales and marketing 24,000 633,000
Professional Fees 1,005,000 446,000
Research and development 340,000 278,000
Depreciation and Amortization 1,145,000 1,119,000
Rent and utilities 74,000 32,000
Impairment of goodwill 25,093,000
Impairment of fixed assets 263,000
Loss on disposal of fixed assets 12,000
Other operating expenses 417,000 171,000
Total costs and expenses 4,314,000 28,753,000
Operating loss (4,282,000) (28,753,000)
Other income (expense):    
Interest income 13,000 13,000
Change in fair value of note payable, related party (9,388,000) 5,068,000
Interest expense (793,000) (1,065,000)
Loss from operations before income taxes (14,450,000) (24,737,000)
Income tax benefit (expense) 2,580,000 (33,000)
Net loss (11,870,000) (24,770,000)
Loss from operations attributed to noncontrolling interest 32,000 62,000
Net loss attributable to common stockholders $ (11,838,000) $ (24,708,000)
Earnings per common share:    
Basic $ (0.38) $ (2.30)
Diluted $ (0.38) $ (2.30)
Shares used in computing loss per common share:    
Basic 31,550,457 10,757,147
Diluted 31,550,457 10,757,147
Biotech Retail Sales [Member]    
Revenue:    
Total revenue $ 32,000